BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chinese Biotech Company Tasly Pharmaceutical to Invest $40 Million in MontCo


6/3/2011 6:59:19 AM

Tasly Group, a biopharmaceutical company based in China, said Thursday it will invest $40 million to take up 430,000 square feet in Montgomery County.

The company will open a production facility and training center for traditional Chinese medicine in the Shady Grove Life Sciences Center. It is the largest investment in Maryland by a Chinese company, according to Gov. Martin O’Malley’s office, and is slated to bring “dozens of jobs” to the state over the next three years.

O’Malley made the announcement following a keynote address on his first full day of a 10-day economic development mission to Asia. Sixty-eight business leaders, politicians and higher education officials have joined O'Malley on the trip.

“By reaching across borders, we can share knowledge and research, generate promising partnerships, and leverage the power of innovation to create jobs and expand opportunity to make our children winners in this changing, global economy,” O’Malley said in a statement.

Tasly is preparing for phase III clinical trials of their Compound Danshen Dripping Pills (CDDP), traditional Chinese medicine developed to treat and prevent coronary disease. The company plans to collaborate with Johns Hopkins University and the other biotech companies located at Shady Grove.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES